Results 281 to 290 of about 1,906,742 (351)

ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice [PDF]

, 2000
Forsthoefel, D, Hartman, M, Hofmeister, J K, Hume, D A, Ostrowski, M C, Schaffner, A E, Smith, J L, Wei, G   +7 more
core  

Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics

Advanced Science, EarlyView.
This review provides a systematic comparison of extracellular vesicles (EVs) from both mammalian and plant sources in the context of autoimmune diseases. It highlights their emerging roles as precision biomarkers and engineered therapeutic platforms.
Yufei Wu, Huiyuan Ma, Tinghui Zhu, Shuwei Huang, Manxi Lu, Qiong Wang, Zai‐Long Chi   +6 more
wiley   +1 more source

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +1 more source

Promoter Hypermethylation‐Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5‐Mediated Wnt/β‐Catenin Pathway Activation

Advanced Science, EarlyView.
This study identifies FXYD1 as an epigenetically silenced tumor suppressor in breast cancer. DNA methylation turns off the gene FXYD1 in breast cancer, and low levels predict worse outcomes. Restoring FXYD1 limits breast cancer cells proliferation and metastasis. In the nucleus, FXYD1 recruits the E3 ligase MAEA to K63‐ubiquitinate DDX5 for proteasomal
Ping Wen, Fanli Qu, Long Wang, Qing Shao, Sisi Li, Yang Qin, Dongping Jiang, Senmiao Zhang, Jiangdong Sui, Guanwen Wang, Ningning Zhang, Xiaohua Zeng   +11 more
wiley   +1 more source

Spatiotemporal profiling of modification-specific proteome secretion uncovers an itaconation-activated tyrosine kinase. [PDF]

Nat Commun
Lu W, Zhang Y, Ni X, Wang P, Zhuang S, Qin W.   +5 more
europepmc   +1 more source

Patient‐Derived 3D‐Bioprinted Intrahepatic Cholangiocarcinoma Models Recapitulate Tumor Autologous Traits and Predict Personalized Adjuvant Therapy

Advanced Science, EarlyView.
Leveraging 3D bioprinting, this study establishes patient‐derived in vitro models of intrahepatic cholangiocarcinoma. These models faithfully recapitulate the histopathology, molecular profiles, and genomic characteristics of the original patient tumors.
Yuce Lu, Liwei Du, Minghao Sun, Kai Zhang, Mingchang Pang, Shangze Jiang, Jiaxun Dong, Xiyue Liu, Bao Jin, Fu Xu, Hang Sun, Jiangang Zhang, Huiyu Yang, Xiaobo Yang, Xin Lu, Yiyao Xu, Haitao Zhao, Shunda Du, Xinting Sang, Yongchang Zheng, Lei Zhang, Xueshuai Wan, Huayu Yang, Yilei Mao   +23 more
wiley   +1 more source

Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide. [PDF]

Oncol Rev
Santamaria F, Roberto M, Maltese G, Nicolella F, Torchia A, Buccilli D, Di Civita MA, Giancontieri P, Marinelli D, Cirillo A, Bianco V, Verrico M, Botticelli A, Santini D.   +13 more
europepmc   +1 more source

Flumonertinib after prior third-generation EGFR-tyrosine kinase inhibitor (TKI) therapy in patients with epidermal growth factor receptor-mutated non-small cell lung cancer after resistance to third-generation tyrosine kinase inhibitor treatment: a real-world study. [PDF]

J Thorac Dis
Wang H, Zhang C, Du S, Wang H.
europepmc   +1 more source

Modulation of the Receptor Tyrosine Kinase TIE2/Tek Pathway by NRF2 Activation in Neurovascular Endothelial Cells. [PDF]

Int J Mol Sci
Cazalla E, García-Yagüe ÁJ, Pajares M, Jiménez-Villegas J, Escoll M, Rojo AI, Cuadrado A.   +6 more
europepmc   +1 more source